Breaking News Instant updates and real-time market news.

WEN

Wendy's

$15.22

-0.25 (-1.62%)

, ACHN

Achillion

$4.01

0.04 (1.01%)

09:15
08/09/17
08/09
09:15
08/09/17
09:15

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Wendy's (WEN), up 2.5%... Achillion (ACHN), up 22.9%... ACADIA (ACAD), up 10.6%... Hertz (HTZ), up 4.3%. DOWN AFTER EARNINGS: Office Depot (ODP), down 13.1%... Childrens Place (PLCE), down 4.9%... Disney (DIS), down 6.1%... Monster Beverage (MNST), down 3%. ALSO LOWER: Netflix (NFLX), down 3.6% after Disney announced it would end its Netflix distribution agreement in 2019.

WEN

Wendy's

$15.22

-0.25 (-1.62%)

ACHN

Achillion

$4.01

0.04 (1.01%)

ACAD

ACADIA

$29.54

-1.03 (-3.37%)

HTZ

Hertz

ODP

Office Depot

$6.11

-0.06 (-0.97%)

PLCE

Children's Place

$118.00

3.55 (3.10%)

DIS

Disney

MNST

Monster Beverage

$52.63

-0.24 (-0.45%)

NFLX

Netflix

$178.36

-2.97 (-1.64%)

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 26

    Sep

WEN Wendy's
$15.22

-0.25 (-1.62%)

05/11/17
SPHN
05/11/17
NO CHANGE
Target $18
SPHN
Overweight
Wendy's price target raised to $18 from $16 at Stephens
Stephens analyst Will Slabaugh said he continues to be impressed by the top-line consistency at Wendy's, which he credits to the continued success of its value offerings and marketing. The analyst, who sees the company winning at both the value and premium ends of the menu, raised his price target on Wendy's to $18 from $16 following its Q1 report and keeps an Overweight rating on the shares.
05/11/17
RHCO
05/11/17
NO CHANGE
RHCO
Wendy's price target raised to $18 from $16 at SunTrust
SunTrust analyst Jake Bartlett continues to expect Wendy's stock to rise, driven by SSS outperformance, new restaurants, and cost cutting. The analyst noted that the company's SSS rose 1.6%, outperforming peers excluding McDonald's (MCD) SSS gain of 0.4%. Bartlett expects the company to continue to do well in 2H17 and he keeps a Buy rating on the shares.
04/21/17
04/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Plains All American (PAA) initiated with an Outperform at Macquarie. 2. Wendy's (WEN) and McDonald's (MCD) were initiated with an Outperform at BMO Capital while Yum! Brands (YUM) was initiated with a Market Perform. 3. Cedar Fair (FUN), Six Flags (SIX), and SeaWorld (SEAS) were initiated with a Buy at Stifel. 4. Domino's Pizza (DPZ) initiated with a Buy at Guggenheim. 5. Cidara Therapeutics (CDTX) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
BMOC
04/21/17
INITIATION
Target $17
BMOC
Outperform
Wendy's initiated with an Outperform at BMO Capital
BMO Capital analyst Andrew Strelzik initiated Wendy's with an Outperform and a $17 price target. The analyst views Wendy's as attractive opportunity given its more defensible premium positioning, strong visibility into achieving long-term targets after structural business model enhancements, and discounted valuation.
ACHN Achillion
$4.01

0.04 (1.01%)

05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.
ACAD ACADIA
$29.54

-1.03 (-3.37%)

03/01/17
LEER
03/01/17
NO CHANGE
Target $36
LEER
Market Perform
ACADIA price target raised to $36 from $31 at Leerink
Leerink analyst Paul Matteis raised his price target for ACADIA to $36 from $31 to reflect quarterly updates and solid sales growth, and greater weight to his revenue multiple analysis. The analyst reiterates a Market Perform rating on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Market Perform
ACADIA data a 'clear upside' but benefit looks modest, says Leerink
Leerink analyst Paul Matteis notes that ACADIA has announced positive top-line data from its Phase 2 study of pimavanserin in Alzheimer's Disease Psychosis. While the analyst believes the benefit looks "modest," he says the announcement represents "clear upside to expectations," which were low into the event. Leerink has a Market Perform on the shares.
04/27/17
LEER
04/27/17
NO CHANGE
Target $50
LEER
Outperform
ACADIA price target lowered to $50 from $55 at Leerink
Leerink analyst Ana Gupte lowered her price target for ACADIA to $50 from $55 due to possible pricing pressures and potential delay in Priory deployment. The analyst reiterates an Outperform rating on the shares.
HTZ Hertz

08/04/17
08/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Neutral at Wedbush. 2. Avis Budget (CAR) was initiated with an Overweight at JPMorgan while Hertz (HTZ) was initiated with a Neutral at the firm. 3. IBM (IBM) initiated with a Neutral at Wedbush. 4. Amtech Systems (ASYS) initiated with a Buy at Roth Capital. 5. Franklin Financial Network (FSB) initiated with a Market Perform at Hovde Group. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
JPMS
08/04/17
INITIATION
Target $15
JPMS
Neutral
Hertz initiated with a Neutral at JPMorgan
JPMorgan analyst Samik Chatterjee started Hertz with a Neutral rating and $15 price target. The analyst believes greater profit growth is possible but sees higher execution risk.
07/31/17
07/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Sell from Hold at Pivotal Research with analyst Brian Wieser saying the shares are not factoring in risks to the company's growth following their "remarkable run" this year. 2. Ulta Beauty (ULTA) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying softer commentary from L'Oreal on its earnings call, increasing promotional activity from the department store channel, and more difficult year-over-year comparisons "could now signal a potentially more challenging beauty backdrop going forward." 3. Hertz (HTZ) downgraded to Underweight from Equal Weight at Barclays with analyst Brian Johnson saying fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21. 4. Citi (C) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing valuation and lack of catalysts. 5. Visteon (VC) downgraded to Neutral from Buy at UBS with analyst Colin Langan saying the risk/reward is more balanced with the shares up 60% over the last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
LEHM
07/31/17
DOWNGRADE
Target $9
LEHM
Underweight
Hertz downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Brian Johnson downgraded Hertz Global Holdings to Underweight with an unchanged price target of $9. Fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21, Johnson tells investors in a research note. He expects a "sharp miss" relative to expectations when Hertz reports Q2 results.
ODP Office Depot
$6.11

-0.06 (-0.97%)

01/30/17
LOOP
01/30/17
NO CHANGE
LOOP
Hold
Loop says Office Depot CEO pick positive, but doesn't change fundamentals
Loop Capital analyst Anthony Chukumba said he views Office Depot's appointment of Gerry Smith as CEO as a positive given his strong technology background and the fact that the hiring reduces senior management uncertainty. However, this one appointment does not eliminate management uncertainty completely and does not change the company's fundamental outlook, said Chukumba, who keeps a Hold rating on the shares.
04/04/17
KEYB
04/04/17
NO CHANGE
KEYB
Staples would be of interest to PE buyers, says KeyBanc
Following The Wall Street Journal report that Staples (SPLS) is exploring a sale and holding talks with possible private equity bidders, KeyBanc analyst Bradley Thomas said he believes the company would be of interest given its strong free cash flow generation and recent actions taken to make its operations more streamlined. Additionally, the rise of Amazon's (AMZN) delivery segment could provide the "silver lining" of making another attempt at a combination of Staples and Office Depot (ODP) possible, Thomas tells investors.
07/12/17
LOOP
07/12/17
NO CHANGE
LOOP
Hold
Office Depot LBO potential doesn't offer significant upside, says Loop Capital
After the recent agreement struck by Staples (SPLS) to go private, Loop Capital analyst Anthony Chukumba examined the leveraged buyout potential of peer Office Depot (ODP). He estimates that a takeover by a private equity sponsor at $7 per share would generate "acceptable, but not awesome" returns, which he concludes provides some level of downside protection but not a significant amount of upside potential for Office Depot shares. Chukumba keeps a Hold rating on Office Depot.
07/31/17
LOOP
07/31/17
NO CHANGE
LOOP
Hold
Loop struggles to see long-term rationale for Office Depot buying Staples stores
After the New York Post said Staples (SPLS) has held talks to sell its 1,500 North American retail stores to Office Depot (ODP), Anthony Chukumba said he believes buying the stores would result in significant synergies for Office Depot and could make near-term sense, but he has a hard time understanding the long-term strategic rationale to "double down" on the secularly declining retail business. Any short-term benefits would be more than offset by the negative long-term implications, believes Chukumba, who keeps a Hold rating on Office Depot shares.
PLCE Children's Place
$118.00

3.55 (3.10%)

06/26/17
TLSY
06/26/17
UPGRADE
TLSY
Outperform
Children's Place upgraded to Outperform from Market Perform at Telsey Advisory
06/09/17
FBRC
06/09/17
NO CHANGE
Target $127
FBRC
Outperform
Children's Place selloff a 'significant' buying opportunity, says FBR Capital
FBR Capital analyst Susan Anderson views the 14% pullback over the past month in shares of Children's Place as a "significant" buying opportunity. The analyst calls her recent meetings with company management "very positive." The meetings supported the analyst's belief that Children's Place "is in a league of its own given" given the company's internal initiatives as well as a "more stable" children's sector. Anderson expects the stock will continue to outperform over the next several years and reiterates an Outperform rating on the name with a $127 price target.
05/22/17
MSCO
05/22/17
NO CHANGE
Target $150
MSCO
Overweight
Children's Place price target raised to $150 from $140 at Morgan Stanley
Morgan Stanley analyst Jay Sole raised Children's Place's price target to $150 and increased his FY17 base case earnings estimate to $7.25, versus consensus of $6.85, and FY18 earnings estimate to $8, versus consensus of $7.50, following the Q1 report. The analyst said the average leases life is below 3 years, 54% of Children's Place stores have a Justice within a one mile radius, eComm business is EBIT margin accretive, and wholesale and international businesses are gaining traction. Sole rates shares an Overweight.
04/19/17
FBRC
04/19/17
NO CHANGE
FBRC
Outperform
Children's Place selloff a 'significant' buying opportunity, says FBR Capital
FBR Capital analyst Susan Anderson views the 12% pullback in shares of Children's Place since the March peak as a "significant" buying opportunity. The stock pulled back yesterday after MScience said the company's comp sales were running down low-single-digits at March-end, Anderson tells investors in a research note. She believes Children's Place's Q1 same-store-sales will "easily" be in line with the positive low-single-digit guidance, if not better, even if sales turned negative at the end of March. Channel checks continue to be positive with promos flattish year-over-year and in-store clearance very lean, the analyst writes. She keeps an Outperform rating on Children's Place.
DIS Disney

08/09/17
FBCO
08/09/17
NO CHANGE
Target $120
FBCO
Outperform
Disney price target lowered to $120 from $125 at Credit Suisse
Credit Suisse analyst Omar Sheikh lowered his price target for Disney to $120 from $125, while reiterating an Outperform rating on the shares. The analyst believes Disney's decision to shift its distribution strategy toward a direct to consumer model leans into the accelerating shifts in video consumption. Ahead is now a period when EPS/free cash flow growth will be diluted by investment, he notes, adding that he believes the company is laying the groundwork for a "stronger future strategically," not least by putting ESPN in a stronger position to successfully renew key sports rights in 2021/2022.
08/09/17
UBSW
08/09/17
NO CHANGE
Target $190
UBSW
Buy
UBS sees little to no impact to Netflix from Disney streaming service launch
UBS analyst Doug Mitchelson noted Disney (DIS) announced plans to launch its own streaming video service in 2019 and said it will not enter into any new licenses with Netflix (NFLX). Disney management has said they still view Netflix as a valuable partner, Mitchelson pointed out. The analyst sees little to no impact to Netflix, noting Disney's offerings will not launch for two years, Disney is adding original content, and he believes the streaming video marketplace will continue to grow. Mitchelson reiterated his Buy rating and $190 price target on Netflix shares.
08/09/17
NEED
08/09/17
NO CHANGE
NEED
Hold
Needham applauds BAMTech acquisition by Disney
Needham analyst Laura Martin is lowering her 2018 estimates for Disney (DIS), but applauds the BAMTech acquisition as a fast-pass way to escape the U.S. TV-bundle box, albeit expensive as the former said it would be modestly dilutive for 2 years. The analyst believes that every content company must follow CBS (CBS) into the direct-to-consumer channel business to maintain growth. Rather than build it, Disney bought this capability which should accelerate time to market, Martin adds. The analyst reiterates a Hold rating on Disney's shares.
08/09/17
MSCO
08/09/17
NO CHANGE
Target $210
MSCO
Overweight
Netflix Overweight thesis remains intact, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne said Netflix's (NFLX) strategy to build its own vertically integrated global content brand will mitigate the loss of Disney (DIS). Swinburne expects some impact to Netflix's second half 2019 when Disney rolls off but said his Overweight thesis and $210 price target remain intact.
MNST Monster Beverage
$52.63

-0.24 (-0.45%)

06/01/17
JEFF
06/01/17
NO CHANGE
JEFF
Jefferies reiterates Monster, Newell as top picks
Jefferies analyst Kevin Grundy reiterates Monster Beverage (MNST) and Newell Brands (NWL) as top picks while addressing "common investor pushbacks." For Monster, the analyst believes improving U.S. results, continued strong international growth and M&A optionality should lead to continued outperformance. For Newell, the analyst sees an attractive valuation and improving organic sales growth. He reiterates Buy ratings on both names.
06/20/17
JEFF
06/20/17
NO CHANGE
Target $63
JEFF
Buy
Monster Beverage looks attractively valued, says Jefferies
Jefferies analyst Kevin Grundy says Monster Beverage remains a top pick following "upbeat commentary" at the company's shareholder meeting. Positives included "bullish" commentary on international growth and margin, an "encouraging" U.S. outlook, and long-term drivers to grow penetration, Grundy tells investors in a research note. He views the shares as attractively valued and reiterates a Buy rating on Monster with a $63 price target.
06/20/17
UBSW
06/20/17
NO CHANGE
Target $59
UBSW
Buy
Monster Beverage growth runway remains attractive, says UBS
UBS analyst Stephen Powers said the Monster Beverage shareholder meeting was highlighted by an upbeat management tone. The team sees its growth coming from international distribution and its top-line growth driven by select innovation, he noted. Powers reiterated his Buy rating and raised his price target to $59 from $57 on Monster Beverage shares.
07/19/17
JEFF
07/19/17
NO CHANGE
JEFF
Jefferies lays out stocks 'overly discounting' Amazon risk
Amazon.com's (AMZN) planned purchase of Whole Foods Market (WFM) has further widened the valuation spread between consumer stocks the market views as resistant to the Aamzon threat and those viewed as vulnerable, Jefferies analysts including Andy Barish and Daniel Binder tells investors in a research note. They believe this dynamic has created opportunities. Specifically, the analysts feel shares of Wal-Mart (WMT), Hain Celestial (HAIN), Foot Locker (FL) and Advance Auto Parts (AAP) are "overly discounting" potential risk from Amazon. Jefferies also believes Casey's General Stores (CASY), Lamb Weston (LW), Murphy USA (MUSA), Monster Beverage (MNST), Starbucks (SBUX) and Ulta Beauty (ULTA) are "well insulated" from Amazon disruption.
NFLX Netflix
$178.36

-2.97 (-1.64%)

08/09/17
JEFF
08/09/17
NO CHANGE
Target $110
JEFF
Hold
Disney likely to create value well above Netflix deal, says Jefferies
Jefferies analyst John Janedis believes the strategic initiatives announced last night by Disney (DIS) are more likely than not to drive long-term value for the company. The potential value creation over the next five years is likely worth "well above" the implied $2B-$3B in Disney's enterprise value from the Netflix (NFLX) distribution deal, Janedis tells investors in a post-earnings research note. He keeps a Hold rating on Disney shares with a $110 price target.
08/09/17
JPMS
08/09/17
NO CHANGE
JPMS
Overweight
Disney exit unlikely to have big impact on Netflix subscribers, says JPMorgan
JPMorgan analyst Doug Anmuth does not expect Disney's (DIS) departure to have a material impact on Netflix's (NFLX) subscriber numbers. While Disney's announcement came earlier than expected, the company's move to go direct is not a surprise, Anmuth tells investors in a research note. He believes Disney (DIS) content likely accounts for a single-digit percentage of Netflix's viewing time. The analyst has an Overweight rating Netflix shares.

TODAY'S FREE FLY STORIES

CRVS

Corvus Pharmaceuticals

$13.00

1.13 (9.52%)

20:37
08/23/17
08/23
20:37
08/23/17
20:37
Upgrade
Corvus Pharmaceuticals rating change  »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$56.28

0.33 (0.59%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Upgrade
Portola Pharmaceuticals rating change  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Feb

TEVA

Teva

$16.49

-0.52 (-3.06%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Downgrade
Teva rating change  »

Teva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 27

    Sep

LOW

Lowe's

$73.01

-2.81 (-3.71%)

20:33
08/23/17
08/23
20:33
08/23/17
20:33
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 21

    Nov

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

, DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

20:25
08/23/17
08/23
20:25
08/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

SJM

J.M. Smucker

$118.85

-1.01 (-0.84%)

TIF

Tiffany

$88.72

0.22 (0.25%)

TTC

Toro Company

$69.02

-1.76 (-2.49%)

SPLS

Staples

$10.18

-0.02 (-0.20%)

BURL

Burlington Stores

$84.95

-1.43 (-1.66%)

MIK

Michaels

$19.61

0.02 (0.10%)

SIG

Signet Jewelers

$51.89

-0.26 (-0.50%)

ANF

Abercrombie & Fitch

$9.61

0.46 (5.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 06

    Sep

  • 03

    Oct

  • 04

    Oct

HSY

Hershey

$107.44

0.34 (0.32%)

19:16
08/23/17
08/23
19:16
08/23/17
19:16
Hot Stocks
Hershey Company to acquire 1.5M common shares from Hershey Trust »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSADY

MS&AD Insurance

$17.08

-0.085 (-0.50%)

19:07
08/23/17
08/23
19:07
08/23/17
19:07
Hot Stocks
MS&AD Insurance to acquire First Capital Insurance in $1.6B deal »

Fairfax Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.00

-1.07 (-0.63%)

18:46
08/23/17
08/23
18:46
08/23/17
18:46
Hot Stocks
Amgen: Lancet Oncology publishes survival analysis from KYPROLIS Phase 3 trial »

Amgen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

GE

General Electric

$24.39

-0.21 (-0.85%)

, ABB

ABB

$23.13

-0.01 (-0.04%)

18:39
08/23/17
08/23
18:39
08/23/17
18:39
Periodicals
GE resumes talks with ABB over industrial solutions deal, Reuters reports »

General Electric (GE) has…

GE

General Electric

$24.39

-0.21 (-0.85%)

ABB

ABB

$23.13

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

  • 02

    Oct

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

, AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

18:17
08/23/17
08/23
18:17
08/23/17
18:17
Periodicals
La-Z-Boy in talks with Amazon over youth shopper outreach, MarketWatch reports »

La-Z-Boy (LZB) is in…

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

VLKAY

Volkswagen

$30.67

0.19 (0.62%)

18:14
08/23/17
08/23
18:14
08/23/17
18:14
Periodicals
VW to launch two-tone compact SUV, Bloomberg says »

Volkswagen plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.71

0.06 (0.56%)

18:01
08/23/17
08/23
18:01
08/23/17
18:01
Hot Stocks
Ford names Jason Luo as chairman, CEO of Ford China »

Ford announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.09

-1.66 (-0.69%)

, LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:47
08/23/17
08/23
17:47
08/23/17
17:47
Periodicals
Boeing 'disappointed' company not chosen for cruise missile deal, Bloomberg says »

Lockheed (LMT), Raytheon…

BA

Boeing

$238.09

-1.66 (-0.69%)

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

RTN

Raytheon

$178.19

-1.03 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HBM

Hudbay Minerals

$8.50

0.2 (2.41%)

17:44
08/23/17
08/23
17:44
08/23/17
17:44
Hot Stocks
Hudbay Minerals acquires 10.76M common shares of Mason Resources »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:32
08/23/17
08/23
17:32
08/23/17
17:32
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees Q4 PC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

GES

Guess

$12.48

0.11 (0.89%)

, TLYS

Tilly's

$9.60

0.88 (10.09%)

17:29
08/23/17
08/23
17:29
08/23/17
17:29
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Guess…

GES

Guess

$12.48

0.11 (0.89%)

TLYS

Tilly's

$9.60

0.88 (10.09%)

WSM

Williams-Sonoma

$43.40

0.55 (1.28%)

PVH

PVH Corp.

$120.04

-0.28 (-0.23%)

YUME

YuMe

$5.15

0.09 (1.78%)

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

HEI

Heico

$81.11

-0.95 (-1.16%)

GBT

Global Blood Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 28

    Sep

MATX

Matson

$24.02

0.24 (1.01%)

17:28
08/23/17
08/23
17:28
08/23/17
17:28
Hot Stocks
Matson upgrading its Honolulu terminal »

Matson announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:24
08/23/17
08/23
17:24
08/23/17
17:24
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:23
08/23/17
08/23
17:23
08/23/17
17:23
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$18.30

-0.1 (-0.54%)

17:21
08/23/17
08/23
17:21
08/23/17
17:21
Recommendations
Civitas Solutions analyst commentary  »

Civitas announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$179.28

-1.39 (-0.77%)

17:20
08/23/17
08/23
17:20
08/23/17
17:20
Hot Stocks
L3 Technologies awarded $172.9M government contract modification »

L-3 Communications Vertex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.08

-1.67 (-0.70%)

17:19
08/23/17
08/23
17:19
08/23/17
17:19
Hot Stocks
Boeing awarded $222.5M government contract modification »

The Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$178.19

-1.03 (-0.57%)

17:18
08/23/17
08/23
17:18
08/23/17
17:18
Hot Stocks
Raytheon awarded approximately $900M government contract »

Raytheon Co., Tucson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:17
08/23/17
08/23
17:17
08/23/17
17:17
Hot Stocks
Lockheed Martin awarded approximately $900M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

, SSNLF

Samsung

$2,020.00

-10 (-0.49%)

17:11
08/23/17
08/23
17:11
08/23/17
17:11
Hot Stocks
HP Inc. sees Samsung deal closing in Q4 »

HP Inc. (HPQ) said it saw…

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

SSNLF

Samsung

$2,020.00

-10 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.